## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. 20549 |  |
|-------------|------------|--|

| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP |
|--|
|--|

| OMB APP                  | OMB APPROVAL |  |  |  |  |  |  |  |
|--------------------------|--------------|--|--|--|--|--|--|--|
| OMB Number:              | 3235-0287    |  |  |  |  |  |  |  |
| Estimated average burden |              |  |  |  |  |  |  |  |
| hours per response:      | 0.5          |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*  Name In Control                           |   | 2. Issuer Name and Ticker or Trading Symbol  Oyster Point Pharma, Inc. [ OYST ] |                                 |                 |   |   |            |                   |  | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |  |   |   |  |           |  |  |  |
|--|---|---|---------------------------------|-----------------|---|---|------------|-------------------|--|---|--|---|---|--|-----------|--|--|--|
| Nau Jeffrey  |   |   |                                 | <u> </u>        |   |   |            |                   |  |   | X  | Director  |   |  | 10% Ow    | ner  |  |  |
| (Last)   | /Eir  | et) (   | Middle)                         |                 | 2 Date of Farlingt Transporting (Month/Dov/Voor)            |   |            |                   |  |   | X  | Officer (   | give title  |  | Other (sp | ecify  |  |  |
| (Last) (First) (Middle) C/O OYSTER POINT PHARMA, INC.                            |   |   |                                 |                 | 3. Date of Earliest Transaction (Month/Day/Year) 07/06/2022 |   |            |                   |  |   |  | President and CEO                                     |   |  |           |  |  |  |
| 202 CARNEGIE CENTER, SUITE 109   |   |   |                                 |                 |   |   |            |                   |  |   |  |   |   |  |           |  |  |  |
|  |   |   |                                 | [               | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |   |            |                   |  |   |  | 6. Individual or Joint/Group Filing (Check Applicable |   |  |           |  |  |  |
| (Street)   | OM  | ,   | 0540                            |                 |   |   |            |                   |  |   |  | Line)   |   | ed by One R  | Reporti   | ng Person  |  |  |
| PRINCET  | ON NJ   | (   | 08540                           |                 |   |   |            |                   |  |   |  | 1   |   | ed by More t   | •         | Ü  | ng   |  |
| (City)   | (Sta  | ate) (  | Zip)                            |                 | Person  |   |            |                   |  |   |  |   |   |  |           |  |  |  |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |   |   |                                 |                 |   |   |            |                   |  |   |  |   |   |  |           |  |  |  |
| Date   |   |   | 2. Transac<br>Date<br>(Month/Da | Execution Date, |   | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) |            |                   | 5. Amount<br>Securities<br>Beneficial<br>Owned Fo<br>Reported  | Form:<br>(D) or   |  | Direct Ir<br>ndirect B<br>r. 4) O                     | Nature of adirect eneficial winership nstr. 4)      |  |           |  |  |  |
|  |   |   |                                 |                 |   |   | Code       | v                 | Amount   | (A) or<br>(D)   | Price  | Transactio  |   |  |           | nstr. 4)   |  |  |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned |   |                                 |                 |   |   |            |                   |  |   |  |   |   |  |           |  |  |  |
|  |   |   | (e                              | e.g., pu        | ts, cal   | ls, warra   | ants,      | option            | s, c   | onvertib  | le secu  | rities)   |   |  |           |  |  |  |
| Derivative Conversion Date   |   | 3. Transaction<br>Date<br>(Month/Day/Year)                                      | e Execution Date                |                 | Code (Instr.  |   | Derivative |                   | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |   | 7. Title and of Securiti Underlying Derivative (Instr. 3 and | ies<br>g<br>Security                                  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s) |           | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|  |   |   |                                 | Cod             | le V  | (A)   | (D)        | Date<br>Exercisat |  | Expiration<br>Date  | Title  | Amount<br>or<br>Number<br>of Shares                   |   | (Instr. 4)   | (5)       |  |  |  |
| Performance<br>Stock Units   | (1)   | 07/06/2022  |                                 | A               |   | 350,000   |            | (2)               |  | 07/05/2032  | Common<br>Stock  | 350,000   | \$0.00  | 350,000  |           | D  |  |  |

## Explanation of Responses:

- 1. Represents a grant of performance stock units (the "PSUs"). Each PSU represents a contingent right to receive one share of Common Stock of the Issuer.
- 2. The PSUs will vest as to (i) 50% on July 6, 2023; and (ii) 50% at such time, if any, beginning on July 6, 2023 and ending on July 6, 2024, the 30 day volume-weighted average stock price reaches \$6.00 per share (the "VWAP Vesting Period"), subject to the Reporting Person's continuous service to the Issuer through each such date. For clarity, the applicable thirty (30) consecutive day period must occur entirely during the VWAP Vesting Period and the thirty (30) day volume-weighted average stock price will be measured during any thirty (30) consecutive trading days during such VWAP Vesting Period.

## Remarks:

/s/ Brandon Fenn, Attorney-in-

Fact

\*\* Signature of Reporting Person

Date

07/08/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.